Recent achievements in colorectal cancer diagnostic and therapy by the use of nanoparticles

Drug Metabolism Reviews

Volumn 48, Issue 1, 2016, Pages 27-46

  Bartoş, Adrian ^a   Bartoş, Dana ^a,b   Szabo, Bianca ^b,c   Breazu, Caius ^b,c   Opincariu, Iulian ^b   Mironiuc, Aurel ^b,d   Iancu, Cornel ^a,b  

^a Octavian Fodor Regional Institute of Gastroenterology and Hepatology   (Romania)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c Cluj County Clinical Emergency Hospital   (Romania)

^d Clinical Emergency County Hospital   (Romania)

Author keywords

chemotherapy; Colorectal cancer; drug resistance; nanotechnology; targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; NANOPARTICLE; CONTRAST MEDIUM;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INHIBITION; CANCER STAGING; CANCER STEM CELL; CANCER THERAPY; COLORECTAL CANCER; CONTROLLED DRUG RELEASE; CYTOTOXICITY; HUMAN; MOLECULAR IMAGING; NANOTECHNOLOGY; NONHUMAN; REVIEW; THERANOSTIC NANOMEDICINE; ANIMAL; CHEMISTRY; COLORECTAL NEOPLASMS; MOLECULARLY TARGETED THERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; CONTRAST MEDIA; HUMANS; MOLECULAR TARGETED THERAPY; NANOPARTICLES;

EID: 84961061503     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.3109/03602532.2015.1130052     Document Type: Review

References (202)

1. Adams VR. (2000). Adverse events associated with chemotherapy for common cancers. Pharmacotherapy 20: 96S-103S
2. Ahmed N, Fessi H, Elaissari A. (2012). Theranostic applications of nanoparticles in cancer. Drug Discov Today 17: 928-934
3. Alexis F, Rhee JW, Richie JP, et al. (2008a). New frontiers in nanotechnology for cancer treatment. Urol Oncol 26: 74-85
4. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. (2008b). Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 5: 505-515
5. Amidi M, Mastrobattista E, Jiskoot W, Hennink WE. (2010). Chitosan-based delivery systems for protein therapeutics and antigens. Adv Drug Deliv Rev 62: 59-82
6. Bae KH, Lee K, Kim C, Park TG. (2011). Surface functionalized hollow manganese oxide nanoparticles for cancer targeted siRNA delivery and magnetic resonance imaging. Biomaterials 32: 176-184
7. Bajaj G, Yeo Y. (2013). Tumor targeted nanoparticles: State of the art and remaining challenges. In: Yeo Y., ed. Nanoparticulate drug delivery systems strategies, technologies and applications. New Jersey: Wiley, 12-21
8. Benezra M, Penate-Medina O, Zanzonico PB, et al. (2011). Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J Clin Investig 121: 2768-2780
9. Benson AB, III, Bekaii-Saab T, Chan E, et al. (2013a). Metastatic colon cancer, version 3.2013: Featured updates to the NCCN Guidelines. J Natl Compreh Cancer Netw 11: 141-152. quiz 52
10. Benson AB, III, Bekaii-Saab T, Chan E, et al. (2013b). Localized colon cancer, version 3.2013: Featured updates to the NCCN Guidelines. J Natl Compreh Cancer Netw 11: 519-528
11. Bertrand N. (2013). Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 66: 2-25
12. Bidwell GL, 3rd, Davis AN, et al. (2007). A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance. Investig New Drugs 25: 313-326
13. Blanco E, Hsiao A, Mann AP, et al. (2011a). Nanomedicine in cancer therapy: Innovative trends and prospects. Cancer Sci 102: 1247-1252
14. Blanco E, Hsiao A, Ruiz-Esparza GU, et al. (2011b). Molecular-targeted nanotherapies in cancer: Enabling treatment specificity. Mol Oncol 5: 492-503
15. Bodnar M, Hartmann J, Borbely J. (2005). Preparation and characterization of chitosan-based nanoparticles. Biomacromolecules 6: 2521-2527
16. Brigger I, Dubernet C, Couvreur P. (2002). Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 54: 631-651
17. Brown SD, Nativo P, Smith JA, et al. (2010). Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin. J Am Chem Soc 132: 4678-4684
18. Bruheim K, Guren MG, Skovlund E, et al. (2010). Late side effects and quality of life after radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 76: 1005-1011
19. Cao J, Zhou NJ. (2005). Progress in antitumor studies of chitosan. Chin J Biochem Pharm 26: 127
20. Cardinal J, Klune JR, Chory E, et al. (2008). Noninvasive radiofrequency ablation of cancer targeted by gold nanoparticles. Surgery 144: 125-132
21. Chang MY, Shiau AL. (2008). Increased apoptotic potential and dose-enhancing effect of gold nanoparticles in combination with single-dose clinical electron beams on tumor-bearing mice. Cancer Sci 99: 1479-1484
22. Chen HH, Yu C, Ueng TH, et al. (1998). Acute and subacute toxicity study of water-soluble polyalkylsulfonated C60 in rats. Toxicol Pathol 26: 143-151
23. Cho K, Wang X, Nie S, et al. (2008). Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 14: 1310-1316
24. Choi KY, Jeon EJ, Yoon HY, et al. (2012). Theranostic nanoparticles based on PEGylated hyaluronic acid for the diagnosis, therapy and monitoring of colon cancer. Biomaterials 33: 6186-6193
25. Choi HS, Liu W, Misra P, et al. (2007a). Renal clearance of quantum dots. Nat Biotechnol 25: 1165-1170
26. Choi J, Burns AA, Williams RM, et al. (2007b). Core-shell silica nanoparticles as fluorescent labels for nanomedicine. J Biomed Opt 12: 064007
27. Chung J, Yokoyama M, Aoyagi T. (1998). Effect of molecular architecture of hydrophobically modified poly (N-isopropylacrylamide) on the formation of thermoresponsive core-shell micellar drug carriers. J Control Release 53: 119-130
28. Consensus Conference. NIH. (1990). Adjuvant therapy for patients with colon and rectal cancer. JAMA 264: 1444-1450
29. Copland JA, Eghtedari M, Popov VL, et al. (2004). Bioconjugated gold nanoparticles as a molecular based contrast agent: Implications for imaging of deep tumors using optoacoustic tomography. Mol Imaging Biol 6: 341-349
30. Cuenca AG, Jiang H, Hochwald SN, et al. (2006). Emerging implications of nanotechnology on cancer diagnostics and therapeutics. Cancer 107: 459-466
31. Culha M, Cullum B, Lavrik N, Klutse C. (2012). Surface-enhanced Raman scattering as an emerging characterization and detection technique. J Nanotechnol 2012: 971380
32. Culha M. (2013). Surface-enhanced Raman scattering: An emerging label-free detection and identification technique for proteins. Appl Spectrosc 67: 355-364
33. Curtin JC, Lorenzi MV. (2010). Drug discovery approaches to target Wnt signaling in cancer stem cells. Oncotarget 1: 552-566
34. De Jong WH, Borm PJ. (2008). Drug delivery and nanoparticles: Applications and hazards. Int J Nanomed 3: 133-149
35. De la Zerda A, Zavaleta C. (2008). Carbon nanotubes as photoacoustic molecular imaging agents in living mice. Nat Nanotechnol 3: 557-562
36. De Jong WH, Hagens WI, Krystek P, et al. (2008). Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials 29: 1912-1919
37. Desai N. (2012). Challenges in development of nanoparticle-based therapeutics. AAPS J 14: 282-295
38. Dhar S, Liu Z, Thomale J. (2008). Targeted single-wall carbon nanotube-mediated Pt(IV) prodrug delivery using folate as a homing device. J Am Chem Soc 130: 11467-11476
39. Dritschilo A, Huang CH, Rudin CM, et al. (2006). Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies. Clin Cancer Res 12: 1251-1259
40. Duncan R, Kreyling WG. (2005). ESF scientific forward look on nanomedicine. Eur Sci Found Pol Brief 19: 1-8
41. Eck W, Craig G, Sigdel A, et al. (2008). PEGylated gold nanoparticles conjugated to monoclonal F19 antibodies as targeted labeling agents for human pancreatic carcinoma tissue. ACS Nano 2: 2263-2272
42. Ediriwickrema A, Saltzman WM. (2015). Nanotherapy for cancer: Targeting and multifunctionality in the future of cancer therapies. ACS Biomater Sci Eng 1: 64-78
43. El-Deeb NM, El-Sherbiny IM. (2015). Novel trend in colon cancer therapy using silver nanoparticles synthesized by honey bee. J Nanomed Nanotechnol 6: 265
44. Elias DM, Sideris L. (2003). Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis. Surg Oncol Clin North Am 12: 755-769
45. Elias D, Bonnay M, Puizillou JM, et al. (2002). Heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: Pharmacokinetic and tissue distribution. Ann Oncol 13: 267-272
46. El-Sayed IH, Huang X, El-Sayed MA. (2005). Surface plasmon resonance scattering and absorption of anti-EGFR antibody conjugated gold nanoparticles in cancer diagnostics: Applications in oral cancer. Nano Lett 5: 829-834
47. Ferrari M. (2005). Cancer nanotechnology: Opportunities and challenges. Nat Rev Cancer 5: 161-171
48. Filion MC, Phillips NC. (1997). Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim Biophys Acta 1329: 345-356
49. Fortina P, Kricka LJ, Graves DJ, et al. (2007). Applications of nanoparticles to diagnostics and therapeutics in colorectal cancer. Trends Biotechnol 25: 145-152
50. Friedhuber AM, Chandolu V, Manchun S, et al. (2015). Nucleotropic doxorubicin nanoparticles decrease cancer cell viability, destroy mitochondria, induce autophagy and enhance tumour necrosis. J Pharm Pharmacol 67: 68-77
51. Fu XY, Besterman JM, Monosov A, Hoffman RM. (1991). Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens. Proc Natl Acad Sci USA 88: 9345-9349
52. Fujiwara K, Armstrong D, Morgan M. (2007). Principles and practice of intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer 17: 1-20
53. Gaitanis A, Staal S. (2010a). Liposomal doxorubicin and nab-paclitaxel: Nanoparticle cancer chemotherapy in current clinical use. In: Grobmyer SR., ed. Cancer nanotechnology methods and protocols. Berlin: Springer, 3863-3890
54. Gaitanis A, Staal S. (2010b). Liposomal doxorubicin and nab-paclitaxel: Nanoparticle cancer chemotherapy in current clinical use. Methods Mol Biol 624: 385-392
55. Gannon CJ, Cherukuri P, Yakobson BI, et al. (2007). Carbon nanotube-enhanced thermal destruction of cancer cells in a noninvasive radiofrequency field. Cancer 110: 2654-2665
56. Gannon CJ, Patra CR, Bhattacharya R, et al. (2008). Intracellular gold nanoparticles enhance non-invasive radiofrequency thermal destruction of human gastrointestinal cancer cells. J Nanobiotechnol 6: 2
57. Gaucher G, Dufresne MH, Sant VP, et al. (2005). Block copolymer micelles: Preparation, characterization and application in drug delivery. J Control Release 109: 169-188
58. Goldberg M, Langer R, Jia X. (2007). Nanostructured materials for applications in drug delivery and tissue engineering. J Biomater Sci Polym Ed 18: 241-268
59. Grabar KC, Brown KR, Keating CD, et al. (1997). Nanoscale characterization of gold colloid monolayers: A comparison of four techniques. Analyt Chem 69: 471-477
60. Grancharov SG, Zeng H, Sun S, et al. (2005). Bio-functionalization of monodisperse magnetic nanoparticles and their use as biomolecular labels in a magnetic tunnel junction based sensor. J Phys Chem B 109: 13030-13035
61. Grobmyer SR, Iwakuma N. (2010). What is cancer nanotechnology? In: Grobmyer SR, Moudgil BM., eds. Cancer nanotechnology, methods in molecular biology. Berlin: Springer Science + Business Media, 1
62. Grudzien P, Lo S, Albain KS, et al. (2010). Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation. Anticancer Res 30: 3853-3867
63. Gu FX, Karnik R, Wang A. (2007). Targeted nanoparticles for cancer therapy. Nano Today 2: 14-21
64. Hainfeld JF, Slatkin DN. (2004). The use of gold nanoparticles to enhance radiotherapy in mice. Phys Med Biol 49: 309-315
65. Haka A, Fitzmaurice KS-P, Crowe M, et al. (2005). Diagnosing breast cancer by using Raman spectroscopy. Proc Natl Acad Sci USA 102: 12371-12376
66. Hankus ME, Li H, Gibson GJ, Cullum BM. (2006). Surface-enhanced Raman scattering-based nanoprobe for high-resolution, non-scanning chemical imaging. Analyt Chem 78: 7535-7546
67. Harisinghani MG, Barentsz J, Hahn PF, et al. (2003). Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348: 2491-2499
68. Harrison LE, Bryan M, Pliner L, Saunders T. (2008). Phase I trial of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy in patients undergoing cytoreduction for advanced intra-abdominal malignancy. Ann Surg Oncol 15: 1407-1413
69. Hartman KB, Wilson LJ, Rosenblum MG. (2008). Detecting and treating cancer with nanotechnology. Mol Diagn Ther 12: 1-14
70. Hatcher H, Planalp R, Cho J, et al. (2008). Curcumin: From ancient medicine to current clinical trials. Cell Mol Life Sci 65: 1631-1652
71. Hawkins M, Soon-Shiong P, Desai N. (2008). Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 60: 876-885
72. Heath JR, Davis ME. (2008). Nanotechnology and cancer. Annu Rev Med 59: 251-265
73. Hegde SR, Sun W, Lynch JP. (2008). Systemic and targeted therapy for advanced colon cancer. Expert Rev Gastroenterol Hepatol 2: 135-149
74. Hirsch LR, Stafford RJ, Bankson JA, et al. (2003). Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci USA 100: 13549-13554
75. Hochwald S. (2011). Molecular-targeted therapy for cancer and nanotechnology. In: Grobmyer SR, Moudgil BM., eds. Cancer nanotechnology methods and protocols. New York: Humana Press, 11-21
76. Hoelen CG, de Mul FF, Pongers R, Dekker A. (1998). Three-dimensional photoacoustic imaging of blood vessels in tissue. Opt Lett 23: 648-650
77. Howell B, Fan D, Rakesh L. (2006). Thermal decomposition of a generation 4.5 PAMAM dendrimer platinum drug conjugate. J Therm Anal Calor. 85: 17-20
78. Huang X, El-Sayed A. (2010). Gold nanoparticles: Optical properties and implementations in cancer diagnosis and photothermal therapy. J Adv Res 1: 13-28
79. Huang X, El-Sayed IH, Qian W, El-Sayed MA. (2006). Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods. J Am Chem Soc 128: 2115-2120
80. Huang X, El-Sayed IH, Qian W, El-Sayed MA. (2007). Cancer cells assemble and align gold nanorods conjugated to antibodies to produce highly enhanced, sharp, and polarized surface Raman spectra: A potential cancer diagnostic marker. Nano Lett 7: 1591-1597
81. Huang HS, Hainfeld JF. (2013). Intravenous magnetic nanoparticle cancer hyperthermia. Int J Nanomed 8: 2521-2532
82. Huang RB, Mocherla S, Heslinga MJ, et al. (2010). Dynamic and cellular interactions of nanoparticles in vascular-targeted drug delivery (review). Mol Membr Biol 27: 190-205
83. Huang X, Li L, Liu T, et al. (2011). The shape effect of mesoporous silica nanoparticles on biodistribution, clearance, and biocompatibility in vivo. ACS Nano 5: 5390-5399
84. Hudson SP, Padera RF, Langer R, Kohane DS. (2008). The biocompatibility of mesoporous silicates. Biomaterials 29: 4045-4055
85. Hume DA. (2006). The mononuclear phagocyte system. Curr Opin Immunol 18: 49-53
86. Hyung Park J, Kwon S, Lee M, et al. (2006). Self-assembled nanoparticles based on glycol chitosan bearing hydrophobic moieties as carriers for doxorubicin: In vivo biodistribution and anti-tumor activity. Biomaterials 27: 119-126
87. Iancu C, Mocan L, Bele C, et al. (2011). Enhanced laser thermal ablation for the in vitro treatment of liver cancer by specific delivery of multiwalled carbon nanotubes functionalized with human serum albumin. Int J Nanomed 6: 129-141
88. Iversen TG, Skotland T, Sandvig K. (2011). Endocytosis and intracellular transport of nanoparticles: Present knowledge and need for future studies. Nano Today 6: 176-185
89. Janib SM, Moses AS. (2010). Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev 62: 1052-1063
90. Jeong Y, Jin S, Kim I. (2010). Doxorubicin-incorporated nanoparticles composed of PEG-grafted carboxymethyl chitosan and antitumor activity against glioma cells in vitro. Colloids Surf B 79: 149-155
91. Jiao Y, Wilkinson J, Di X, et al. (2009). Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood 113: 462-469
92. Johnson RL, Fleet JC. (2013). Animal models of colorectal cancer. Cancer Metastasis Rev 32: 39-61
93. Jones R, Cheung C, Black F. (2003). Poly(2-alkylacrylic acid) polymers deliver molecules to the cytosol by pH-sensitive disruption of endosomal vesicles. Biochem J 372: 65-75
94. Jonker DJ, Spithoff K, Maroun J., Gastrointestinal Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based C. (2011). Adjuvant systemic chemotherapy for Stage II and III colon cancer after complete resection: An updated practice guideline. Clin Oncol 23: 314-322
95. Jun YW, Huh YM, Choi JS. (2005). Nanoscale size effect of magnetic nanocrystals and their utilization for cancer diagnosis via magnetic resonance imaging. J Am Chem Soc 127: 5732-5733
96. Kamata H, Tasaka S, Inoue K, et al. (2011). Carbon black nanoparticles enhance bleomycin-induced lung inflammatory and fibrotic changes in mice. Exp Biol Med (Maywood) 236: 315-324
97. Karmakar A, Iancu C, Bartos DM, et al. (2012). Raman spectroscopy as a detection and analysis tool for in vitro specific targeting of pancreatic cancer cells by EGF-conjugated, single-walled carbon nanotubes. J Appl Toxicol 32: 365-375
98. Kelland L. (2007). The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7: 573-584
99. Kickelbick G, Schubert US. (2003). Advances in nanophase materials and nanotechnology. In: Baraton MI., ed. Functionalization and surface treatment of nanoparticles. Valencia (CA): American Scientific Publishers, 91-102
100. Kim K, Kim JH, Park H, et al. (2010). Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring. J Control Release 146: 219-227
101. Kitayama J. (2014). Intraperitoneal chemotherapy against peritoneal carcinomatosis: Current status and future perspective. Surg Oncol 23: 99-106
102. Klaunig JE, Kamendulis LM, Hocevar BA. (2010). Oxidative stress and oxidative damage in carcinogenesis. Toxicol Pathol 38: 96-109
103. Ko H, Tsukruk VV. (2008). Nanoparticle-decorated nanocanals for surface-enhanced Raman scattering. Small 4: 1980-1984
104. Kobayashi H, Kawamoto S, Brechbiel MW, et al. (2005). Detection of lymph node involvement in hematologic malignancies using micromagnetic resonance lymphangiography with a gadolinum-labeled dendrimer nanoparticle. Neoplasia 7: 984-991
105. Kohler N, Sun C, Wang J, Zhang M. (2005). Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells. Langmuir 21: 8858-8864
106. Kolitz-Domb M, Gringerg I, Margel S. (2014). Engineering of near infrared fluorescent proteinoid-poly(L-lactic acid) particles for in vivo colon cancer detection. J Nanobiotechnol 12: 30
107. Kono K, Ozawa T, Yoshida T, et al. (2010). Highly temperature-sensitive liposomes based on a thermosensitive block copolymer for tumor-specific chemotherapy. Biomaterials 31: 7096-7105
108. Lammers T, Hennink WE, Storm G. (2008). Tumour-targeted nanomedicines: Principles and practice. Br J Cancer 99: 392-397
109. Laroui H, Rakhya P, Xiao B, et al. (2013). Nanotechnology in diagnostics and therapeutics for gastrointestinal disorders. Digest Liver Dis 45: 995-1002
110. Lee S, Park Y, Zuidema MY, et al. (2011). Effects of interventions on oxidative stress and inflammation of cardiovascular diseases. World J Cardiol 3: 18-24
111. Li KC, Pandit SD, Guccione S, Bednarski MD. (2004). Molecular imaging applications in nanomedicine. Biomed Microdevices 6: 113-116
112. Lim DK, Jeon KS, Kim HM, et al. (2010). Nanogap-engineerable Raman-active nanodumbbells for single-molecule detection. Nat Mater 9: 60-67
113. Liu D, Yi C, Zhang D, et al. (2010). Inhibition of proliferation and differentiation of mesenchymal stem cells by carboxylated carbon nanotubes. ACS Nano 4: 2185-2195
114. Liu T, Li L, Fu C. (2012). Pathological mechanisms of liver injury caused by continuous intraperitoneal injection of silica nanoparticles. Biomaterials 33: 2399-2407
115. Llevot A, Astruc D. (2012). Applications of vectorized gold nanoparticles to the diagnosis and therapy of cancer. Chem Soc Rev 41: 242-257
116. Maeda H, Matsumura Y. (1989). Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst 6: 193-210
117. Mahmood M, Casciano DA, Mocan T, et al. (2010). Cytotoxicity and biological effects of functional nanomaterials delivered to various cell lines. J Appl Toxicol 30: 74-83
118. Mahmood M, Karmakar A, Fejleh A, et al. (2009). Synergistic enhancement of cancer therapy using a combination of carbon nanotubes and anti-tumor drug. Nanomedicine (Lond) 4: 883-893
119. Mak IW, Evaniew N, Ghert M. (2014). Lost in translation: Animal models and clinical trials in cancer treatment. Am J Transl Res 6: 114-118
120. Mamaeva V, Rosenholm JM, Bate-Eya LT, et al. (2011). Mesoporous silica nanoparticles as drug delivery systems for targeted inhibition of Notch signaling in cancer. Mol Ther 19: 1538-1546
121. Maynard AD, Warheit DB, Philbert MA. (2011). The new toxicology of sophisticated materials: Nanotoxicology and beyond. Toxicol Sci 120: S109-S129
122. Mirkin CA, Letsinger RL, Mucic RC, Storhoff JJ. (1996). A DNA-based method for rationally assembling nanoparticles into macroscopic materials. Nature 382: 607-609
123. Mocan L, Tabaran FA, Mocan T, et al. (2011). Selective ex-vivo photothermal ablation of human pancreatic cancer with albumin functionalized multiwalled carbon nanotubes. Int J Nanomed 6: 915-928
124. Mocan L, Ilie I, Tabaran FA, et al. (2013). Surface plasmon resonance-induced photoactivation of gold nanoparticles as mitochondria-targeted therapeutic agents for pancreatic cancer. Expert Opin Ther Targets 17: 1383-1393
125. Mocan T, Matea CT, Cojocaru I, et al. (2014). Photothermal treatment of human pancreatic cancer using PEGylated multi-walled carbon nanotubes induces apoptosis by triggering mitochondrial membrane depolarization mechanism. J Cancer 5: 679-688
126. Moghimi SM, Hunter AC, Murray JC. (2001). Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol Rev 53: 283-318
127. Moreau LC, Rajan R, Thirlwell MP, Alcindor T. (2013). Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant setting. Anticancer Res 33: 1765-1768
128. Moskovits M. (1978). Surface roughness and the enhanced intensity of Raman scattering by molecules adsorbed on metal. J Chem Phys 69: 4159-4161
129. Murphy CJ, Gole AM, Stone JW, et al. (2008). Gold nanoparticles in biology: Beyond toxicity to cellular imaging. Acc Chem Res 41: 1721-1730
130. National Comprehensive Cancer Network Guidelines version 2. 2015a. Colon Cancer 2015. Available from: http://www.nccn.org [last accessed 22 Jul 2015]
131. National Comprehensive Cancer Network Guidelines version 2. 2015b. Rectal Cancer 2015. Available from: http://www.nccn.org [last accessed 22 Jul 2015]
132. Nehoff H, Taurin S, Greish K. (2013). Toxical assessment of nanomedicine. In: Yeo Y., ed. Nanoparticulate drug delivery systems strategies, technologies and applications. New Jersey: Wiley, 289-317
133. Nemmar A, Nemery B, Hoet PH, et al. (2005). Silica particles enhance peripheral thrombosis: Key role of lung macrophage-neutrophil cross-talk. Am J Respir Crit Care Med 171: 872-879
134. Nichols JW, Bae YH. (2013). Drug delivery strategies for combating multiple drug resistance. In: Yeo Y., ed. Nanoparticulate drug delivery systems strategies, technologies and applications. New Jersey: Wiley, 2452-2458
135. Nishiyama N, Kataoka K. (2006). Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol Ther 112: 630-648
136. O'Brien ME, Wigler N, Inbar M, et al. (2004). Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15: 440-449
137. Oh N, Park J. (2014). Endocytosis and exocytosis of nanoparticles in mammalian cells. Int J Nanomed 9: 51-63
138. Ohya Y, Shiratani M, Kobayashi H. (1994). Release behavior of 5-fluorouracil from chitosan-gel nanospheres immobilizing 5-fluorouracil coated with polysaccharides and their cell specific cytotoxicity. J Macromol Sci A 31: 629-642
139. O'Neal DP, Hirsch LR, Halas NJ, et al. (2004). Photo-thermal tumor ablation in mice using near infrared-absorbing nanoparticles. Cancer Lett 209: 171-176
140. Patel VP, Chu CT. (2011). Nuclear transport, oxidative stress, and neurodegeneration. Int J Clin Exp Pathol 4: 215-229
141. Peer D, Karp JM. (2007). Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2: 751-760
142. Pesic M, Podolski-Renic A, Stojkovic S, et al. (2015). Anti-cancer effects of cerium oxide nanoparticles and its intracellular redox activity. Chem Biol Interact 232: 85-93
143. Pilati P, Mocellin S, Cr R. (2003). Doxorubicin activity is enhanced by hyperthermia in a model of ex-vivo vascular perfusion of human colon carcinoma. World J Surg 27: 640-646
144. Poland CA, Duffin R, Kinloch I, et al. (2008). Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. Nat Nanotechnol 3: 423-428
145. Popat A, Hartono SB, Stahr F, et al. (2011). Mesoporous silica nanoparticles for bioadsorption, enzyme immobilisation, and delivery carriers. Nanoscale 3: 2801-2818
146. Prabaharan M, Mano J. (2004). Chitosan-based particles as controlled drug delivery systems. Drug Deliv 12: 41-57
147. Rapoport N, Pitt WG, Sun H, Nelson JL. (2003). Drug delivery in polymeric micelles: From in vitro to in vivo. J Control Release 91: 85-95
148. Rayson D, Urquhart R, Cox M, et al. (2012). Adherence to clinical practice guidelines for adjuvant chemotherapy for colorectal cancer in a Canadian province: A population-based analysis. J Oncol Pract Am Soc Clin Oncol 8: 253-259
149. Rejinold N, Chennazhi K, Nair S. (2011). Biodegradable and thermo-sensitive chitosan-g-poly(N-vinylcaprolactam) nanoparticles as a 5-fluorouracil carrier. Carbohydr Polym 83: 776-786
150. Rosenberg DW, Giardina C, Tanaka T. (2009). Mouse models for the study of colon carcinogenesis. Carcinogenesis 30: 183-196
151. Rosenholm JM, Peuhu E, Bate-Eya LT, et al. (2010). Cancer-cell-specific induction of apoptosis using mesoporous silica nanoparticles as drug-delivery vectors. Small 6: 1234-1241
152. Ross JF, Chaudhuri PK, Ratnam M. (1994). Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 73: 2432-2443
153. Ruckenstein E, Li ZF. (2005). Surface modification and functionalization through the self-assembled monolayer and graft polymerization. Adv Colloid Interface Sci 113: 43-63
154. Salerno M, Yahia D, Dzamitika S. (2009). Impact of intracellular chloride concentration on cisplatin accumulation in sensitive and resistant GLC4 cells. J Biol Inorg Chem 14: 123-134
155. Salmenkylä S, Kour M, Österlund P. (2012). Does preoperative radiotherapy with postoperative chemotherapy increase acute side-effects and postoperative complications of total mesorectal excision? Report of the randomized Finnish rectal cancer trial. Scand J Surg 101: 275-282
156. Schroeder A, Honen R, Turjeman K, et al. (2009). Ultrasound triggered release of cisplatin from liposomes in murine tumors. J Control Release 137: 63-68
157. Schulz-Dobrick M, Sarathy KV, Jansen M. (2005). Surfactant-free synthesis and functionalization of gold nanoparticles. J Am Chem Soc 127: 12816-12817
158. Shabaruddin FH, Chen LC, Elliott RA, Payne K. (2013). A systematic review of utility values for chemotherapy-related adverse events. PharmacoEconomics 31: 277-288
159. Sharma P, Brown S, Bengtsson N. (2008). Gold-speckled multimodal nanoparticles for noninvasive bioimaging. Chem Mater 20: 6087-6094
160. Shi XY, Fan XG. (2002). Advances in nanoparticle system for delivering drugs across the biological barriers. China Pharm Univ 33: 169-172
161. Shim G, Park J, Roh L. (2013). Applications of Ligand-Engineered Nanomedicines. In: Yeo Y., ed. Nanoparticulate drug delivery systems strategies, technologies and applications. New Jersey: John Wiley & Sons, 33-60
162. Shvedova AA, Castranova V, Kisin ER, et al. (2003). Exposure to carbon nanotube material: Assessment of nanotube cytotoxicity using human keratinocyte cells. J Toxicol Environ Health A 66: 1909-1926
163. Siegel R, Ma J, Zou Z, Jemal A. (2014a). Cancer statistics, 2014. Cancer J Clin 64: 9-29
164. Siegel R, Desantis C, Jemal A. (2014b). Colorectal cancer statistics, 2014. Cancer J Clin 64: 104-117
165. Singh R, Lillard J. (2009). Nanoparticle-based targeted drug delivery. Exp Mol Pathol 86: 215-223
166. Singh P, Gupta U, Asthana A, Jain NK. (2008). Folate and folate-PEG-PAMAM dendrimers: Synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice. Bioconjug Chem 19: 2239-2252
167. Sonavane G, Tomoda K, Makino K. (2008). Biodistribution of colloidal gold nanoparticles after intravenous administration: Effect of particle size. Colloids Surf B Biointerfaces 66: 274-280
168. Su K, Wei Q, Zhang X. (2003). Interparticle coupling effects on plasmon resonances of nanogold particles. Nano Lett 3: 1087-1090
169. Subbiah R, Veerapandian M, Yun KS. (2010). Nanoparticles: Functionalization and multifunctional applications in biomedical sciences. Curr Med Chem 17: 4559-4577
170. Sun C, Lee JS, Zhang M. (2008). Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev 60: 1252-1265
171. Taketo MM, Edelmann W. (2009). Mouse models of colon cancer. Gastroenterology 136: 780-798
172. Tiernan JP, Ingram N, Marston G, et al. (2015). CEA-targeted nanoparticles allow specific in vivo fluorescent imaging of colorectal cancer models. Nanomedicine10: 1223-1231
173. Todd RC, Lippard SJ. (2009). Inhibition of transcription by platinum antitumor compounds. Metallom Integr Biometal Sci 1: 280-291
174. Torre LA, Bray F, Siegel RL, et al. (2015). Global cancer statistics, 2012. Cancer J Clin 65: 87-108
175. Tritton TR. (1991). Cell surface actions of adriamycin. Pharmacol Ther 49: 293-309
176. Tsuchiya T, Oguri I, Yamakoshi YN, Miyata N. (1996). Novel harmful effects of [60]fullerene on mouse embryos in vitro and in vivo. FEBS Lett 393: 139-145
177. Van der Speeten K, Stuart OA, Sugarbaker PH. (2012). Pharmacology of perioperative intraperitoneal and intravenous chemotherapy in patients with peritoneal surface malignancy. Surg Oncol Clin North Am 21: 577-597
178. Varga C, Szendi K. (2010). Carbon nanotubes induce granulomas but not mesotheliomas. In Vivo 24: 153-156
179. Vega-Villa KR, Takemoto JK, Yanez JA, et al. (2008). Clinical toxicities of nanocarrier systems. Adv Drug Deliv Rev 60: 929-938
180. Verma A, Uzun O, Hu Y. (2008). Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles. Nat Mater 7: 588-595
181. von Moos R, Thuerlimann BJ, Aapro M. (2008). Pegylated liposomal doxorubicin-associated hand-foot syndrome: Recommendations of an international panel of experts. Eur J Cancer 44: 781-790
182. Wang JJ, Zeng ZW, Xiao RZ, et al. (2011a). Recent advances of chitosan nanoparticles as drug carriers. Int J Nanomed 6: 765-774
183. Wang K, Liu L, Zhang T, et al. (2011b). Oxaliplatin-incorporated micelles eliminate both cancer stem-like and bulk cell populations in colorectal cancer. Int J Nanomed 6: 3207-3218
184. Wang K, Zhang T, Liu L, et al. (2012). Novel micelle formulation of curcumin for enhancing antitumor activity and inhibiting colorectal cancer stem cells. Int J Nanomed 7: 4487-4497
185. Wang K, Wu X, Wang J, Huang J. (2013). Cancer stem cell theory: Therapeutic implications for nanomedicine. Int J Nanomed 8: 899-908
186. Weissleder R, Kelly K, Sun EY, et al. (2005). Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol 23: 1418-1423
187. Weiswald LB, Richon S, Validire P, et al. (2009). Newly characterised ex vivo colospheres as a three-dimensional colon cancer cell model of tumour aggressiveness. Br J Cancer 101: 473-482
188. Weizenecker J, Gleich B, Rahmer J, et al. (2009). Three-dimensional real-time in vivo magnetic particle imaging. Phys Med Biol 54: L1-L10
189. Weng KC, Noble CO, Papahadjopoulos-Sternberg B, et al. (2008). Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo. Nano Lett 8: 2851-2857
190. Wessels A, Van Berlo D, Boots AW, et al. (2011). Oxidative stress and DNA damage responses in rat and mouse lung to inhaled carbon nanoparticles. Nanotoxicology 5: 66-78
191. Wilton-Ely JD. (2008). The surface functionalisation of gold nanoparticles with metal complexes. Dalton Trans 1: 25-29
192. Wong HL, Rauth AM, Bendayan R, et al. (2006). A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm Res 23: 1574-1585
193. Wu J, Wang C, Sun J, Xue Y. (2011). Neurotoxicity of silica nanoparticles: Brain localization and dopaminergic neurons damage pathways. ACS Nano 5: 4476-4489
194. Xu X, Zhou J, Li L. (2008). Preparation of doxorubicin-loaded chitosan polymeric micell and study on its tissue biodistribution in mice. Acta Pharm Sin 43: 743-748
195. Yamashita K, Yoshioka Y, Higashisaka K, et al. (2011). Silica and titanium dioxide nanoparticles cause pregnancy complications in mice. Nat Nanotechnol 6: 321-328
196. Yang X, Skrabalak S. (2007). Photoacoustic tomography of a rat cerebral cortex in vivo with au nanocages as an optical contrast agent. Nano Lett 7: 3798-3802
197. Yatvin MB, Lelkes PI. (1982). Clinical prospects for liposomes. Med Phys 9: 149-175
198. Yoshida S, Hiyoshi K, Oshio S, et al. (2010). Effects of fetal exposure to carbon nanoparticles on reproductive function in male offspring. Fertil Steril 93: 1695-1699
199. Yu T, Malugin A, Ghandehari H. (2011). Impact of silica nanoparticle design on cellular toxicity and hemolytic activity. ACS Nano 5: 5717-5728
200. Zhang L, Radovic-Moreno AF, Alexis F, et al. (2007). Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates. ChemMedChem 2: 1268-1271
201. Zhang XD, Wu D, Shen X, et al. (2011). Size-dependent in vivo toxicity of PEG-coated gold nanoparticles. Int J Nanomed 6: 2071-2081
202. Zhou Y, Yang J, Kopecek J. (2012). Selective inhibitory effect of HPMA copolymer-cyclopamine conjugate on prostate cancer stem cells. Biomaterials 33: 1863-1872.